t******o
发帖数: 6493 | | D******9
发帖数: 2665 | 2 难道Cabo对前列腺癌没有效果？ 过两天就知道了。 | s******a
发帖数: 318 | 3 为什么过两天就知道了？
【在 D******9 的大作中提到】
: 难道Cabo对前列腺癌没有效果？ 过两天就知道了。
| s**********9
发帖数: 846 | 4 who still have it?
i have 1000 shares. | D******9
发帖数: 2665 | 5 Exelixis, Inc. (EXEL) today announced that its lead compound, cabozantinib,
will be the subject of three clinical data presentations at the European
Society for Medical Oncology (ESMO) 2012 Congress. During the meeting, which
will be held from September 28 to October 2, 2012, in Vienna, Austria,
investigators will present data from ongoing trials of cabozantinib in
medullary thyroid cancer, castration-resistant prostate cancer, and non-
small cell lung cancer. | D******9
发帖数: 2665 | | D******9
发帖数: 2665 | 7 结果出来了
Exelixis Reports Positive Interim Data
Exelixis reported that 40 milligram doses of its cabozantinib drug appear to
have similar results as larger doses in reducing metastatic bone and soft
tissue disease. The preliminary data based on phase II trials was released
over the weekend. EXEL climbs 4 percent in early trading. | T**********s
发帖数: 647 | |
|
